Senti Biosciences, Inc. (NASDAQ:SNTI) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Senti Biosciences, Inc. (NASDAQ:SNTI) have received an average rating of “Moderate Buy” from the five brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $9.00.

SNTI has been the topic of a number of research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a research note on Thursday, January 22nd. Chardan Capital lifted their target price on shares of Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Finally, Wall Street Zen raised shares of Senti Biosciences to a “sell” rating in a report on Saturday, December 13th.

Senti Biosciences Stock Performance

Shares of SNTI stock opened at $0.88 on Thursday. The stock has a market cap of $23.16 million, a PE ratio of -0.26 and a beta of 2.12. Senti Biosciences has a 1 year low of $0.80 and a 1 year high of $5.10. The stock has a fifty day moving average price of $0.95 and a 200 day moving average price of $1.39.

Hedge Funds Weigh In On Senti Biosciences

Institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC purchased a new stake in shares of Senti Biosciences in the second quarter valued at $1,883,000. Geode Capital Management LLC increased its position in Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after purchasing an additional 117,588 shares in the last quarter. Citadel Advisors LLC acquired a new position in Senti Biosciences in the 3rd quarter valued at about $117,000. Virtu Financial LLC purchased a new position in Senti Biosciences in the 4th quarter valued at about $46,000. Finally, Jane Street Group LLC purchased a new position in Senti Biosciences in the 4th quarter valued at about $40,000. 25.70% of the stock is owned by institutional investors and hedge funds.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.